RELATED CONTENT
NEWS
- Filing for first-line NSCLC subset to open new door for Tarceva in Japan
- NICE: does off-patent docetaxel change costing for Roche's Tarceva?
- NICE's draft guidance rejects Lilly's Alimta in NSCLC expanded maintenance indication
- ArQule says Kyowa's ATTENTION deficit won't affect MARQUEE Phase III tivantinib study
COMMENT
Other Informa Comment

